Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$483.00 USD

483.00
2,259,829

-15.73 (-3.15%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

BioDelivery (BDSI) Q4 Earnings and Revenues Beat Estimates

BioDelivery (BDSI) beats earnings and sales expectations for the fourth quarter of 2019.

Has Vertex Pharmaceuticals (VRTX) Outpaced Other Medical Stocks This Year?

Is (VRTX) Outperforming Other Medical Stocks This Year?

Sanghamitra Saha headshot

5 Top Stocks With Great Earnings Beat Potential

These top-ranked stocks are likely to beat on the bottom line in their next release.

Why Is Vertex (VRTX) Down 2.7% Since Last Earnings Report?

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Perrigo (PRGO) Misses Q4 Earnings Estimates, Tops Revenues

Perrigo (PRGO) reports mixed fourth-quarter 2019 results. The addition of products following Ranir acquisition boosts sales in the quarter. Stock declines.

Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Miss Estimates

Sarepta (SRPT) reports wider year-over-year loss. However, revenues increase year over year.

BioMarin (BMRN) Q4 Earnings Beat, Sales Miss, Valrox in Focus

BioMarin (BMRN) announces mixed results for the fourth quarter of 2019, beating estimates for earnings while missing the same for sales.

Has Vertex Pharmaceuticals (VRTX) Outpaced Other Medical Stocks This Year?

Is (VRTX) Outperforming Other Medical Stocks This Year?

3 Reasons Why Vertex (VRTX) Is a Great Growth Stock

Vertex (VRTX) possesses solid growth attributes, which could help it handily outperform the market.

Looking for a Growth Stock? Why It is Time to Focus on Vertex (VRTX)

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Vertex (VRTX).

Puma (PBYI) Stock Down Despite Q4 Earnings & Sales Beat

Puma Biotech (PBYI) incurs narrower loss in Q4 and tops sales estimates. Sales of Nerlynx decline year over year. Stock drops 10%.

Surging Earnings Estimates Signal Good News for Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals (VRTX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Kinjel Shah headshot

What's in Store for Vertex in 2020 After a Remarkable 2019?

In 2020, Vertex's (VRTX) sales are expected to be primarily driven by Trikafta and higher international revenues.

AstraZeneca's (AZN) Q4 Earnings and Sales Miss Estimates

AstraZeneca (AZN) misses estimates for earnings and sales. However, new drugs, mainly cancer medicines, continue to drive product sales higher.

Pfizer's Xtandi Improves OS Rate in Prostate Cancer Study

Pfizer's (PFE) Xtandi demonstrates a significant improvement in overall survival in the late-stage PROSPER study that evaluated the drug in men with non-metastatic castration-resistant prostate cancer.

Zacks.com featured highlights include: Chipotle Mexican Grill, Vertex Pharmaceuticals, ResMed, Spirit Airlines and OneMain

Zacks.com featured highlights include: Chipotle Mexican Grill, Vertex Pharmaceuticals, ResMed, Spirit Airlines and OneMain

Swayta Shah headshot

Buy These 5 Stocks With Attractive Sales Growth Right Now

Sales growth is an important metric for any company, as it is a vital part of growth projections and instrumental in strategic decision making.

Sweta Killa headshot

Momentum ETFs & Stocks to Buy on Renewed Market Rally

Momentum investing would be a winning strategy for those seeking higher returns in a short spell. This is because the strategy seeks to capitalize on the continuance of an existing market trend.

3 Reasons Growth Investors Will Love Vertex (VRTX)

Vertex (VRTX) possesses solid growth attributes, which could help it handily outperform the market.

Why Vertex (VRTX) Might be Well Poised for a Surge

Vertex (VRTX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Is Vertex Pharmaceuticals (VRTX) Stock Outpacing Its Medical Peers This Year?

Is (VRTX) Outperforming Other Medical Stocks This Year?

Biotech Stock Roundup: Earnings Updates From VRTX, AMGN, GILD; AIMT Gains FDA Nod

Many biotech bigwigs came out with their fourth-quarter numbers in the past week.

Vertex (VRTX) Hits 52-Week High, Can the Run Continue?

Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Benjamin Rains headshot

Buy this Cloud-Based Business Services Stock After Earnings on Strong Growth?

ServiceNow posted stronger-than-projected Q4 2019 results on January 29. Analysts have since raised their fiscal 2020 and 2021 earnings estimates for the fast-growing, cloud-focused business services firm...

Vertex (VRTX) Q4 Earnings Beat on Solid CF Product Sales

Vertex (VRTX) rides high on earnings and revenue beat in Q4. The company provides solid outlook for 2020 resulting in the shares to go up in after-hours trading.